These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8614294)

  • 1. The vesamicol receptor ligand (+)-meta-[125I]iodobenzyltrozamicol [(+)-[125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease.
    Efange SM; Langason RB; Khare AB; Low WC
    Life Sci; 1996; 58(16):1367-74. PubMed ID: 8614294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding.
    Efange SM; Langason RB; Khare AB
    J Nucl Med; 1996 Jul; 37(7):1192-7. PubMed ID: 8965197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and tissue distribution of (m-[125I]iodobenzyl)trozamicol ([125I]MIBT): potential radioligand for mapping central cholinergic innervation.
    Efange SM; Michelson RH; Khare AB; Thomas JR
    J Med Chem; 1993 Jun; 36(12):1754-60. PubMed ID: 8510103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats.
    Araki T; Tanji H; Fujihara K; Kato H; Imai Y; Mizugaki M; Itoyama Y
    J Neural Transm (Vienna); 2000; 107(8-9):873-84. PubMed ID: 11041269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
    Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
    J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
    Zhang C; Steiner JP; Hamilton GS; Hicks TP; Poulter MO
    J Neurosci; 2001 Aug; 21(15):RC156. PubMed ID: 11459877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
    Dluzen D
    Brain Res; 1997 Sep; 767(2):340-4. PubMed ID: 9367266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
    Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
    Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.
    Christopher L; Marras C; Duff-Canning S; Koshimori Y; Chen R; Boileau I; Segura B; Monchi O; Lang AE; Rusjan P; Houle S; Strafella AP
    Brain; 2014 Feb; 137(Pt 2):565-75. PubMed ID: 24334314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
    Vorobyov VV; Schibaev NV; Morelli M; Carta AR
    Brain Res; 2003 May; 972(1-2):177-85. PubMed ID: 12711091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET.
    Nikolaus S; Larisch R; Beu M; Forutan F; Vosberg H; Müller-Gärtner HW
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):390-5. PubMed ID: 12634967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors.
    Liste I; Rozas G; Guerra MJ; Labandeira-Garcia JL
    Brain Res; 1995 Nov; 700(1-2):1-12. PubMed ID: 8624698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain.
    Mendlin A; Martín FJ; Jacobs BL
    Neuroscience; 1999; 93(3):897-905. PubMed ID: 10473255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.